BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37016153)

  • 1. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
    Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
    JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
    Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars for the treatment of psoriasis.
    Puig L; López-Ferrer A
    Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
    [No Abstract]   [Full Text] [Related]  

  • 9. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
    Ruda RC; Kelly KA; Feldman SR
    J Dermatolog Treat; 2023 Dec; 34(1):2140569. PubMed ID: 36305624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in Dermatology - theory becomes reality.
    Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
    Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J
    Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
    Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
    BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study.
    Kearsley-Fleet L; Baildam E; Beresford MW; Douglas S; Foster HE; Southwood TR; Hyrich KL;
    Lancet Rheumatol; 2024 Jun; ():. PubMed ID: 38843858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
    Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of rheumatology biosimilars in the absence of forced switching.
    Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
    Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
    Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
    Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    Sci Rep; 2022 Nov; 12(1):19569. PubMed ID: 36380105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.